+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rhabdomyosarcoma - Pipeline Review, H2 2019

  • ID: 4901282
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 418 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Alxerion Biotech Corp
  • Cellectar Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • MacroGenics Inc
  • Oncolys BioPharma Inc
  • Sorrento Therapeutics Inc
  • MORE
Rhabdomyosarcoma - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2019, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.

Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhabdomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 20, 9, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 1 and 2 molecules, respectively.

Rhabdomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Rhabdomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rhabdomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rhabdomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rhabdomyosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rhabdomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alxerion Biotech Corp
  • Cellectar Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • MacroGenics Inc
  • Oncolys BioPharma Inc
  • Sorrento Therapeutics Inc
  • MORE
Introduction
Report Coverage
Rhabdomyosarcoma - Overview
Rhabdomyosarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rhabdomyosarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rhabdomyosarcoma - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
Alxerion Biotech Corp
Amgen Inc
Arisaph Pharmaceuticals Inc
Bayer AG
Biogenera SpA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cellectar Biosciences Inc
Cellestia Biotech AG
Eisai Co Ltd
Epizyme Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Galapagos NV
ImmunityBio Inc
Iproteos SL
Ipsen SA
MacroGenics Inc
Mana Therapeutics Inc
NanoRED Biotechnology
NantKwest Inc
Novartis AG
Oncoheroes Biosciences Inc
Oncolys BioPharma Inc
Oxurion NV
Pfizer Inc
Provectus Biopharmaceuticals Inc
Seneca Therapeutics Inc
Shionogi & Co Ltd
Sorrento Therapeutics Inc
Taiho Pharmaceutical Co Ltd
Taiwan Liposome Co Ltd
Tarveda Therapeutics Inc
Veana Therapeutics LLC
Zenyaku Kogyo Co Ltd
Rhabdomyosarcoma - Drug Profiles
Rhabdomyosarcoma - Dormant Projects
Rhabdomyosarcoma - Discontinued Products
Rhabdomyosarcoma - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Rhabdomyosarcoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Rhabdomyosarcoma - Pipeline by Advenchen Laboratories LLC, H2 2019
Rhabdomyosarcoma - Pipeline by Alxerion Biotech Corp, H2 2019
Rhabdomyosarcoma - Pipeline by Amgen Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Arisaph Pharmaceuticals Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Bayer AG, H2 2019
Rhabdomyosarcoma - Pipeline by Biogenera SpA, H2 2019
Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Rhabdomyosarcoma - Pipeline by Bristol-Myers Squibb Co, H2 2019
Rhabdomyosarcoma - Pipeline by Cellectar Biosciences Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Cellestia Biotech AG, H2 2019
Rhabdomyosarcoma - Pipeline by Eisai Co Ltd, H2 2019
Rhabdomyosarcoma - Pipeline by Epizyme Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Exelixis Inc, H2 2019
Rhabdomyosarcoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Rhabdomyosarcoma - Pipeline by Galapagos NV, H2 2019
Rhabdomyosarcoma - Pipeline by ImmunityBio Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Iproteos SL, H2 2019
Rhabdomyosarcoma - Pipeline by Ipsen SA, H2 2019
Rhabdomyosarcoma - Pipeline by MacroGenics Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Mana Therapeutics Inc, H2 2019
Rhabdomyosarcoma - Pipeline by NanoRED Biotechnology, H2 2019
Rhabdomyosarcoma - Pipeline by NantKwest Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Novartis AG, H2 2019
Rhabdomyosarcoma - Pipeline by Oncoheroes Biosciences Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Oncolys BioPharma Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Oxurion NV, H2 2019
Rhabdomyosarcoma - Pipeline by Pfizer Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Provectus Biopharmaceuticals Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Seneca Therapeutics Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Shionogi & Co Ltd, H2 2019
Rhabdomyosarcoma - Pipeline by Sorrento Therapeutics Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019
Rhabdomyosarcoma - Pipeline by Taiwan Liposome Co Ltd, H2 2019
Rhabdomyosarcoma - Pipeline by Tarveda Therapeutics Inc, H2 2019
Rhabdomyosarcoma - Pipeline by Veana Therapeutics LLC, H2 2019
Rhabdomyosarcoma - Pipeline by Zenyaku Kogyo Co Ltd, H2 2019
Rhabdomyosarcoma - Dormant Projects, H2 2019
Rhabdomyosarcoma - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Rhabdomyosarcoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Advenchen Laboratories LLC
  • Alxerion Biotech Corp
  • Amgen Inc
  • Arisaph Pharmaceuticals Inc
  • Bayer AG
  • Biogenera SpA
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Cellectar Biosciences Inc
  • Cellestia Biotech AG
  • Eisai Co Ltd
  • Epizyme Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • ImmunityBio Inc
  • Iproteos SL
  • Ipsen SA
  • MacroGenics Inc
  • Mana Therapeutics Inc
  • NanoRED Biotechnology
  • NantKwest Inc
  • Novartis AG
  • Oncoheroes Biosciences Inc
  • Oncolys BioPharma Inc
  • Oxurion NV
  • Pfizer Inc
  • Provectus Biopharmaceuticals Inc
  • Seneca Therapeutics Inc
  • Shionogi & Co Ltd
  • Sorrento Therapeutics Inc
  • Taiho Pharmaceutical Co Ltd
  • Taiwan Liposome Co Ltd
  • Tarveda Therapeutics Inc
  • Veana Therapeutics LLC
  • Zenyaku Kogyo Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll